Biopharmaceutical Aspects of Lipid Formulations of Amphotericin B

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1997 Jan 1

PMID 9063676

Citations 10

Authors

G Storm

E van Etten

Affiliations

Soon will be listed here.

Abstract

To improve the clinical utility of amphotericin B (AmpB), several lipid-based formulations have been developed. The biopharmaceutical aspects related to the parenteral use of colloidal lipid particles as carriers of AmpB are reviewed here. The first part of the review provides an introduction to the parenteral use of colloidal particles for chemotherapy by addressing the concept of a particulate drug carrier system, the pharmaceutical technological issues, and the biological factors governing the potential and limitations of lipid particles for effective drug delivery. The second part is devoted to AmpB lipid formulations. The pharmaceutical characteristics of the various industrially produced formulations, their pharmacokinetics and possible mechanisms of action, and potential future developments are described.

Citing Articles

Plasma Bead Entrapped Liposomes as a Potential Drug Delivery System to Combat Fungal Infections.

Fatima M, Islam Z, Ahmad E, Hoque M, Yamin M Molecules. 2022; 27(3).

PMID: 35164370 PMC: 8840493. DOI: 10.3390/molecules27031105.

Combination of Posaconazole and Amphotericin B in the Treatment of Biofilms.

Rodrigues C, Alves D, Henriques M Microorganisms. 2018; 6(4).

PMID: 30518069 PMC: 6313645. DOI: 10.3390/microorganisms6040123.

Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.

Rodrigues C, Henriques M Pathogens. 2017; 6(4).

PMID: 29194382 PMC: 5750586. DOI: 10.3390/pathogens6040062.

Improved antifungal activity of amphotericin B-loaded TPGS-b-(PCL-ran-PGA) nanoparticles.

Tang X, Jiao R, Xie C, Xu L, Huo Z, Dai J Int J Clin Exp Med. 2015; 8(4):5150-62.

PMID: 26131089 PMC: 4483864.

Pharmacological properties of antifungal drugs with a focus on anidulafungin.

Mazzei T, Novelli A Drugs. 2009; 69 Suppl 1:79-90.

PMID: 19877739 DOI: 10.2165/11315550-000000000-00000.

References

Taylor R, Williams D, Craven P, Graybill J, Drutz D, Magee W . Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis. 1982; 125(5):610-1. DOI: 10.1164/arrd.1982.125.5.610. View

Lichtenberg D, Barenholz Y . Liposomes: preparation, characterization, and preservation. Methods Biochem Anal. 1988; 33:337-462. DOI: 10.1002/9780470110546.ch7. View

Belay T, Hospenthal D, ROGERS A, Patterson M . Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model. J Med Vet Mycol. 1991; 29(6):419-21. DOI: 10.1080/02681219180000671. View

Gabizon A, Papahadjopoulos D . Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988; 85(18):6949-53. PMC: 282096. DOI: 10.1073/pnas.85.18.6949. View

Wasan K, Lopez-Berestein G . Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins. Ann N Y Acad Sci. 1994; 730:93-106. DOI: 10.1111/j.1749-6632.1994.tb44242.x. View

de Marie S, Janknegt R . Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother. 1994; 33(5):907-16. DOI: 10.1093/jac/33.5.907. View

Hospenthal D, ROGERS A, BENEKE E . Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother. 1989; 33(1):16-8. PMC: 171413. DOI: 10.1128/AAC.33.1.16. View

Van Etten E, ten Kate M, Stearne L . Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother. 1995; 39(9):1954-8. PMC: 162862. DOI: 10.1128/AAC.39.9.1954. View

Morgan J, Williams L, Howard C . Technetium-labelled liposome imaging for deep-seated infection. Br J Radiol. 1985; 58(685):35-9. DOI: 10.1259/0007-1285-58-685-35. View

10.

Jain R . Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990; 9(3):253-66. DOI: 10.1007/BF00046364. View

11.

Belay T, Hospenthal D, ROGERS A, Patterson M . Treatment of systemic candidiasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B. Mycopathologia. 1993; 123(1):9-17. DOI: 10.1007/BF01103483. View

12.

Woodle M, Lasic D . Sterically stabilized liposomes. Biochim Biophys Acta. 1992; 1113(2):171-99. DOI: 10.1016/0304-4157(92)90038-c. View

13.

Senior J . Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst. 1987; 3(2):123-93. View

14.

Uziely B, Jeffers S, Isacson R, Kutsch K, Yehoshua Z, Libson E . Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995; 13(7):1777-85. DOI: 10.1200/JCO.1995.13.7.1777. View

15.

Lopez-Berestein G, Bodey G, Fainstein V, Keating M, Frankel L, Zeluff B . Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989; 149(11):2533-6. View

16.

Williams B, OSullivan M, Saggu G, Williams K, Williams L, Morgan J . Synovial accumulation of technetium labelled liposomes in rheumatoid arthritis. Ann Rheum Dis. 1987; 46(4):314-8. PMC: 1002126. DOI: 10.1136/ard.46.4.314. View

17.

Presant C, Scolaro M, Kennedy P, Blayney D, Flanagan B, Lisak J . Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet. 1993; 341(8855):1242-3. DOI: 10.1016/0140-6736(93)91147-e. View

18.

Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan M, Keating M . Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985; 151(4):704-10. DOI: 10.1093/infdis/151.4.704. View

19.

Jain R . Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989; 81(8):570-6. DOI: 10.1093/jnci/81.8.570. View

20.

Perkins W, Minchey S, Boni L, Swenson C, Popescu M, Pasternack R . Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta. 1992; 1107(2):271-82. DOI: 10.1016/0005-2736(92)90414-h. View